Neoplasm Grading

• 

  Subject Areas on Research

  • 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. 
  • 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL. 
  • A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. 
  • A Review and Update on Papillary Immature Metaplasia of the Uterine Cervix: A Distinct Subset of Low-Grade Squamous Intraepithelial Lesion, Proposing a Possible Cell of Origin. 
  • A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. 
  • A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). 
  • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. 
  • A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma. 
  • A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. 
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. 
  • A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. 
  • A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. 
  • ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. 
  • ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer. 
  • ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. 
  • ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. 
  • Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. 
  • Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. 
  • Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? 
  • Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. 
  • Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. 
  • Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. 
  • African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect? 
  • African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. 
  • African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. 
  • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 
  • Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. 
  • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 
  • An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. 
  • An update on noninvasive follicular thyroid neoplasm with papillary-like nuclear features. 
  • Analysis of perioperative radiation therapy in the surgical treatment of primary and recurrent retroperitoneal sarcoma. 
  • Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. 
  • Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging. 
  • Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer. 
  • Artificial Intelligence-assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. 
  • Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. 
  • Assessment of intra-observer variability in measurement of high-grade brain tumors. 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. 
  • BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. 
  • Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. 
  • Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men. 
  • Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study. 
  • Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. 
  • Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? 
  • Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. 
  • Cabozantinib in genitourinary malignancies. 
  • Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? 
  • Cancer Outcomes in DCIS Patients Without Locoregional Treatment. 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Cellular Blue Nevomelanocytic Lesions: Analysis of Clinical, Histological, and Outcome Data in 37 Cases. 
  • Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI. 
  • Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. 
  • Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). 
  • Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. 
  • Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. 
  • Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers. 
  • Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 
  • Concordant, non-atypical breast papillomas do not require surgical excision: A 10-year multi-institution study and review of the literature. 
  • Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. 
  • Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? 
  • Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions. 
  • Defining a textbook surgical outcome for patients undergoing surgical resection of intermediate and high-grade soft tissue sarcomas of the extremities. 
  • Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. 
  • Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. 
  • Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). 
  • Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. 
  • Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. 
  • Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy. 
  • Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men. 
  • Differential expression of immune related genes in high-grade ovarian serous carcinoma. 
  • Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. 
  • Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. 
  • Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? 
  • Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. 
  • Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. 
  • Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. 
  • Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. 
  • Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. 
  • Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. 
  • Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. 
  • Evidence of a genetic link between endometriosis and ovarian cancer. 
  • Evolution of Focal Therapy in Prostate Cancer: Past, Present, and Future. 
  • Evolving management of low grade glioma: No consensus amongst treating clinicians. 
  • Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. 
  • Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience. 
  • Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. 
  • Familial gliomas: cases in two pairs of brothers. 
  • Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study. 
  • Fibrosarcoma-like lipomatous neoplasm: a reappraisal of so-called spindle cell liposarcoma defining a unique lipomatous tumor unrelated to other liposarcomas. 
  • First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. 
  • First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and white women. 
  • Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. 
  • Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. 
  • Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. 
  • Frequency of breast cancer subtypes among African American women in the AMBER consortium. 
  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. 
  • GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". 
  • Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. 
  • Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. 
  • Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. 
  • Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. 
  • Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. 
  • Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. 
  • Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. 
  • Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. 
  • HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. 
  • High-fructose corn syrup enhances intestinal tumor growth in mice. 
  • High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. 
  • Histotype classification of ovarian carcinoma: A comparison of approaches. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. 
  • Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. 
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. 
  • Improved grading of IDH-mutated astrocytic gliomas. 
  • Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas. 
  • In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. 
  • In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. 
  • Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. 
  • Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. 
  • Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution. 
  • Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia. 
  • Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. 
  • Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? 
  • Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. 
  • LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia. 
  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. 
  • Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46. 
  • Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. 
  • Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. 
  • Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. 
  • MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2. 
  • MYC/BCL2 double-hit high-grade B-cell lymphoma. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. 
  • Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. 
  • Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. 
  • Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. 
  • Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk. 
  • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. 
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. 
  • Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7? 
  • Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. 
  • Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. 
  • Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. 
  • Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. 
  • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? 
  • Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. 
  • Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. 
  • Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. 
  • Obesity, weight gain, and ovarian cancer risk in African American women. 
  • Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. 
  • Open surgical partial nephrectomy for upper tract urothelial carcinoma. 
  • Open versus laparoscopic portal lymphadenectomy in gallbladder cancer: is there a difference in lymph node yield? 
  • Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy. 
  • Pancreatic Neuroendocrine Tumors. 
  • Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. 
  • Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. 
  • Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. 
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. 
  • Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. 
  • Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. 
  • Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. 
  • Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. 
  • Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. 
  • Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry. 
  • Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. 
  • Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. 
  • Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. 
  • Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. 
  • Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. 
  • Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. 
  • Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. 
  • Prior tonsillectomy is associated with an increased risk of esophageal adenocarcinoma. 
  • Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. 
  • Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. 
  • Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. 
  • Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. 
  • Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. 
  • RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. 
  • Race-associated biological differences among Luminal A breast tumors. 
  • Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. 
  • Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. 
  • Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. 
  • Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). 
  • Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. 
  • Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. 
  • Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer. 
  • Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? 
  • Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. 
  • Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. 
  • Role of Increased n-acetylaspartate Levels in Cancer. 
  • Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. 
  • Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze. 
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. 
  • Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing? 
  • Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. 
  • Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. 
  • Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? 
  • Should New "No Ink On Tumor" Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. 
  • Simpson Grade I-III Resection of Spinal Atypical (World Health Organization Grade II) Meningiomas is Associated With Symptom Resolution and Low Recurrence. 
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. 
  • Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. 
  • Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. 
  • Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers? 
  • Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. 
  • Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? 
  • Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. 
  • Surveillance after prostate focal therapy. 
  • Survival and low-grade glioma: the emergence of genetic information. 
  • Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. 
  • Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. 
  • Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? 
  • Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. 
  • The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. 
  • The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. 
  • The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. 
  • The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? 
  • The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. 
  • The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. 
  • The Role of Surgery for Pancreatic Neuroendocrine Tumors. 
  • The association between sexual function and prostate cancer risk in US veterans. 
  • The effect of the setting of a positive surgical margin in soft tissue sarcoma. 
  • The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. 
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. 
  • The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. 
  • The role of magnetic resonance imaging in delineating clinically significant prostate cancer. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • The use of fluorescein sodium in the biopsy and gross-total resection of a tectal plate glioma. 
  • The use of radiation therapy in localized high-grade soft tissue sarcoma and potential impact on survival. 
  • Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. 
  • Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. 
  • Transcript expression in endometrial cancers from Black and White patients. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. 
  • Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. 
  • Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. 
  • US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. 
  • Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. 
  • Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. 
  • Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). 
  • Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. 
  • Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. 
  • Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. 
  • [Femur reconstruction using combined autologous fibula transfer and humeral allograft]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Roy Choudhury, Kingshuk, Adjunct Associate Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Yan, Hai, Adjunct Professor of Pathology, Pathology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society